PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
An online gallery comprised of the best art from the very best artists. Rise Art uses artificial intelligence alongside consumer psychology to produce personalised recommendations, which customers can 'trial' out in their personal spaces, or workplaces, to see if it meets their desires. In 2017, the company had grown with £1m in sales, almost twice YoY.
days to go:
Expired
investment:
£690,680
Nextfin is an FCA approved aggregation and rating portal for equity and debt crowdfunding investments.
AIM is shrinking, legacy stock markets are too expensive to maintain and do not serve the requirements of SMEs, banks are closing branches, lending less and are paying little or no interest to investors. As a result of this, there is a huge growth in equity crowdfunding and P2P lending which has seen the launch of hundreds of alternative lenders & platforms that has created a new c.£3bn marketplace, expanding at 66% p.a. There is no single portal or trusted ratings index for investors to compare on a like for like basis and no secondary market to facilitate exits.
* NextFin is the new trading name of Business Agent Ltd
The solution
NextFin aggregates equity and debt crowdfunding investments to create the alternative finance marketplace. This makes it easy for investors and lenders to find and compare opportunities by presenting all investment offerings in one place. With the addition of a free of charge ratings service investors will be able to view ratings of every equity crowdfunding pitch, every P2P site, and every equity crowdfunding site. NextFin’s technology will constantly track these companies and investments providing the investor real-time intelligence on which to base investment decisions. The platforms and entrepreneurs will be self-promoting and marketing their ratings driving thousands of visitors a month to the NextFin site, in the same way, businesses refer their potential clients to Trip Advisor and Trustpilot. There is an estimated 10 million website/platform visitors per month across the whole of the alternative finance market. NextFin is targeting to direct 5% of this highly profiled traffic to its platform from which it will earn between £5-£8 per click from advertisers and partners. In addition, an in-house brokerage service also earns between 1%-6% commissions on loan placements. A future revenue stream (not featured in the financials) will be developed once visitor traffic reaches critical mass. This will see Nextfin being able to realise the full value of its captured ratings data and visitor traffic by launching a secondary market, which is estimated to be a £5bn marketplace.
NextFin is raising £500k at a pre-money valuation of £2M to: • Develop P2P and Equity site ratings• Expand the management, infrastructure and marketing resource• Increase visitor traffic to 6m a year via rating referrals
Owing to the size of the market and rapid growth of the industry, enterprise valuations in alternative finance are based on visitor traffic, market share and registered users. Recently published valuations of companies with visitor traffic of over 6m per year are in excess of £70m. NextFin is the market-leading aggregator and has first-mover advantage. It has the potential to exceed these valuations because it is the whole of the market aggregator and is currently the only ratings service provider as it grows to achieve 500,000 visitors p.m.
days to go:
Expired
investment:
£274,057
A web-based location experience platform for businesses to market their content for their target audience by users visiting physical locations to view digital content. Landmrk's service is currently used by travel, entertainment and retail industries and allows businesses to provide 'rewards' when customers reach the location. Revenue is primarily generated from marketing agencies and businesses licensing the platform on a monthly, quartely or annual basis.
days to go:
Expired
investment:
£519,364
Emopwering people to improve their musculoskeletal health through exercise. TrackActive is a physical health app that assesses a person's conditions, health and habits and delivers a personalised programme consisting of advice and exercises that adapt as the person progresses. The app is developed using rehabilitative exercise data, clinical algorithms and AI. The app can be used by organisations to view anonymised information on the health of their employees or customers and is distributed via public health, corporate and insurance partners.
TrackActive will be monetised via the aforementioned partners, who will pay an ongoing monthly subscription from £25 per month. This figure may increase depending on the health practitioners using the service. TrackActive's content, such as articles, video and images, can also be licensed to partners. Funds will be allocated towards developing the product further, with the inclusion of an Android version, admin dashboards, evidence-based content and regular updates to the app.
days to go:
Expired
investment:
£253,598
Milbotix, a healthtech start-up, supported by the Alzheimer's Society and the UK Dementia Research Institute, is driven by its innovative product SmartSocks™. This wearable technology aims to assist individuals with dementia facing communication challenges and their caregivers. Globally, the number of people with dementia is increasing significantly, reaching 78 million by 2030 and 139 million by 2050. Half of those diagnosed with dementia encounter challenging behavioral symptoms due to distress. Early distress management not only enhances well-being but also helps prevent escalating behavioral issues. SmartSocks™ utilize sensors and artificial intelligence to notify dementia caregivers about early signs of pain and anxiety in their patients.
days to go:
Expired
investment:
£220,780
